Pitt Shield

Low-frequency HIFU induced cancer immunotherapy: tempting challenges and potential opportunities.

Authors: Shi G, Zhong M, Ye F, Zhang X

Immunotherapy is playing an increasingly important role in the treatment of tumors. Different from the traditional direct killing or excision therapies, immunotherapy depends on autologous immunity to kill tumor cells and tissues by activating or enhancing the body's immune system. Large numbers of recent studies suggest that low-frequency HIFU can not only enhance the intensity of the body's anti-cancer immune response, but also improve the efficiency of immunotherapy drug delivery to strengthen the effects of tumor immunotherapy. The focused ultrasound (FUS) destructs the tumor and simultaneously generates tumor debris and tumor-associated antigens, which enhances the immunogenicity of the tumor and stimulates the immune cells, inducing the body's immune response. Microbubbles are clinically used as a contrast. As a matter of fact, the addition of microbubbles can reinforce the destructive effect of FUS on the tumor and activate a stronger immune response. The combined application of ultrasound and microbubbles can more effectively open the blood brain barrier (BBB), which is beneficial to improving the intake of immune cells or immunotherapy drugs and exerting a positive influence in the lesion area. Currently, microbubbles and nanoparticles are commonly used as gene and drug carriers. Using ultrasound, the immune-related gene or antigen delivery itself can enhance the immune response and improve the efficacy of the immunotherapy.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To evaluate how low-frequency high-intensity focused ultrasound (HIFU) can activate and enhance anti-tumor immune responses and improve delivery of immunotherapies.
Disease model Cancer (tumor)
Cargo name and characteristics Tumor-associated antigens (protein/antigen); immune-related genes (nucleic acid gene therapy cargo); nanoparticles (nanoparticle carriers for genes/drugs); immunotherapy drugs (unspecified therapeutic agents)

Outcomes and Safety

Summary of Outcomes Low‑frequency, low‑temperature (non‑thermal/cavitation) focused ultrasound (FUS/HIFU) enhances anti‑tumor immunity by producing tumor antigens, recruiting and maturing dendritic cells, inhibiting tumor growth and promoting apoptosis, and improves delivery of immunotherapies by opening the BBB and facilitating microbubble/nanoparticle‑mediated gene/drug delivery; combining low‑frequency HIFU with immunotherapy produced better results than immunotherapy alone. Successful FUS parameters reported: low‑frequency/low‑temperature (non‑thermal/cavitation) HIFU, use of microbubbles to amplify cavitation and open the BBB, and ultrasound‑mediated delivery using microbubbles or nanoparticles.
Safety-related matter No specific adverse effects are reported. The authors caution generally about avoiding damage to normal tissues and advise weighing advantages/disadvantages of high-temperature HIFU (more ablative) versus low-temperature HIFU (more immunogenic), and note complexities with microbubble carriers (half-life and penetration), but no safety outcomes are presented.

Brain Region

Visualization unavailable

Ultrasound Parameters

Focal Characteristics Focal depth: None; Focal length: None; Aperture size: None

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search